Previous studies have confirmed that the KEAP1/NRF2 system could be an important therapeutic target for various diseases, including inflammatory diseases (40), diabetes (41), and neurodegenerative diseases (42). This evidence concerns the gene KEAP1 and diabetes mellitus.